Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2000

View Archived Issues

MDS Nordion to manufacture Altropane diagnostic agent

Lynx Therapeutics enters partnership to identify diabetes-associated SNPs

Dendreon describes therapeutic cancer vaccine technology

NIH offers V1 knockout mice for S. pneumoniae vaccine screening

Peptide vaccines available for licensing from NIH

cDNA clones of tick-borne flavivirus available for licensing from NIH

Suplatast tosilate improves asthma symptoms in a double-blind trial

Malaria incidence and resistance controlled by artesunate-mefloquine treatment

Research links development of type 1 diabetes with inflammation

Mechanism of resistance to ABL tyrosine kinase inhibitor STI-571 explored

Potent, selective human A2B adenosine receptor antagonists reported

Orally active dual NK1/NK2 antagonist synthesized by Schering-Plough

Selective ICAM-1 and E-selectin inhibitors on human endothelial cells explored

Wyeth-Ayerst recommends that certain lots of Norplant not be implanted

Psoriasis therapy proceeds to clinical trials

Interneuron enrolls first patients in phase I/II study of PRO-2000 Gel

Syntheses and SAR presented for DuPont Pharmaceuticals' CRF receptor antagonists

Orphan Medical's Antizol sNDA accepted for filing

FDA approves Santen's levofloxacin eyedrops

Inex's Onco TCS given fast track status

New series of PARP inhibitors claimed by Guilford

Elan and Biogen establish Antegren collaboration agreement

Novel compounds useful for neurological disorders claimed by AstraZeneca

Seven key sessions and symposia from XXII ESC Congress available to Daily Essentials readers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...